IGI licenses Nova Skin dermatologist sales duties to "major" drug company.
This article was originally published in The Rose Sheet
Executive SummaryIGI ACTIVEL SKIN CARE LINE TO BOW IN 1997 in the salon/esthetician market. IGI is working on the skin care line, which employs the company's patented Novasome lipid microvesicle technology, with San Jose, Calif.-based Image Enhancing Dermatology (IED), a physician group partnership that specializes in medical and cosmetic dermatology. IGI and IED announced their partnership Aug. 21 ("The Rose Sheet" Aug. 26, p. 6)
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.